Abciximab API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

Located in:

Belgium
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Abciximab API 143653-53-6?

Description:
Here you will find a list of producers, manufacturers and traders of Abciximab. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Abciximab 
Synonyms:
antiGPIIBIIIa , C7E3  
Cas Number:
143653-53-6 
DrugBank number:
DB00054 
Unique Ingredient Identifier:
X85G7936GV

About Abciximab

So, what does it do? Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements

Abciximab is a type of Glycoprotein IIb/IIIa receptor antagonists


Glycoprotein IIb/IIIa receptor antagonists belong to a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medicine. These antagonists specifically target and inhibit the activity of the glycoprotein IIb/IIIa receptors found on platelets.

The glycoprotein IIb/IIIa receptors play a crucial role in platelet aggregation, which is an essential step in the formation of blood clots. By blocking these receptors, glycoprotein IIb/IIIa receptor antagonists prevent platelets from binding to each other and forming clots, thereby inhibiting thrombus formation.

These pharmaceutical compounds have shown great potential in the treatment and prevention of conditions related to unwanted blood clotting, such as acute coronary syndromes and percutaneous coronary interventions. They are commonly used during angioplasty and stent placement procedures to reduce the risk of clot formation and subsequent complications.

Glycoprotein IIb/IIIa receptor antagonists are typically administered intravenously and have a relatively short duration of action. Common examples include abciximab, eptifibatide, and tirofiban. These agents are carefully monitored and controlled due to their potent antiplatelet effects.

It is important to note that the use of glycoprotein IIb/IIIa receptor antagonists requires close medical supervision, as they can increase the risk of bleeding. Therefore, healthcare professionals must carefully weigh the benefits and risks when considering the administration of these pharmaceutical APIs.


Abciximab (Glycoprotein IIb/IIIa receptor antagonists), classified under Anticoagulants


Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.

There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.

Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.

While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.

In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.



Abciximab manufacturers | traders | suppliers

We have 1 companies offering Abciximab produced in 1 different countries.

Get in contact with the supplier of your choice:

  • Janssen Pharma from Belgium, product country of origin Netherlands

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.